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Seven-mer phage random peptide libraries were panned against 2C10, a monoclonal antibody that showed neutralizing activities against
PEDV. Recombinant M13 phages displaying the peptides SHRLP(Y/Q)(P/V) or GPRPVTH on the g3p minor coat protein showed strong binding
affinity with 2C10 (70% and 30% of recovered phages, respectively) after multiple panning. Sequence analysis suggested that these peptides are
similar with 1368GPRLQPY1374 found at the carboxy-terminal of the S protein. In neutralization inhibition assays, the two peptide motifs and a 24-
mer synthetic peptide corresponding to the C-terminal endodomain of PEDV S protein were observed to compete for the antigen binding site of
2C10, as demonstrated by the loss or reduction of neutralizing activity of the monoclonal antibody. This new finding suggests that the newly
discovered peptide motifs mimic a neutralizing epitope PEDV.
© 2006 Elsevier Inc. All rights reserved.Keywords: PEDV; Spike protein; Phage display library; Neutralizing epitope; Synthetic peptidesIntroduction
Porcine epidemic diarrhea virus (PEDV) belongs to the
family Coronaviridae and is closely related with human
coronavirus 229E, transmissible gastroenteritis virus and feline
infectious peritonitis virus (Bridgen et al., 1993; Yaling et al.,
1988). This virus causes porcine epidemic diarrhea, an enteric
disease affecting swine of all ages. It is characterized by acute
watery diarrhea and dehydration (DeBouck and Pensaert,
1980). The clinical and pathological symptoms are similar to
those of another swine coronaviral disease, transmissible
gastroenteritis, making it difficult to differentiate between the
two (Pospischil et al., 1981; Pritchard et al., 1999).
During the past decade, PED infection has been a major
concern in the swine industry, particularly in the Asian region,
resulting in large economic losses (Chae et al., 2000, Sueyoshi
et al., 1995). Because of the economic importance of PED in the
swine industry, measures to control the spread of the disease
have led to the development of live attenuated vaccines. It
began with the work of Hofmann and Wyler (1988) when they⁎ Corresponding author. Fax: +82 42 825 2993.
E-mail address: shin0089@cnu.ac.kr (H.-J. Shin).
0042-6822/$ - see front matter © 2006 Elsevier Inc. All rights reserved.
doi:10.1016/j.virol.2006.04.027successfully propagated PEDV in Vero cells. Later, Bernasconi
et al. (1995) reported that after multiple passages of PEDV
CV777 in Vero cells, the cell adapted strain differed
significantly from the parental strain both in terms of genomic
sequence and pathogenicity. In a similar study, Kweon et al.
(1999) reported that another cell adapted strain of PEDV
induced protective immunity in pregnant sows that were
transferable to lactating piglets. However, in spite of these
developments, PED still persist in several provinces in the
Asian region. Thus, there is a need to understand the mechanism
of viral entry and pathogenesis. Such information would be
valuable in developing more effective vaccines in the future.
In this study, we screened a phage displayed peptide library
for peptides with sequence or structural similarity with a PEDV
neutralizing epitope. Candidate phage-displayed peptides
selected by multiple panning were tested for inhibition
properties against a monoclonal antibody with known neutral-
izing activity against the KPEDV-9 vaccine strain. The peptides
displayed on these phages were compared with known sequence
of PEDV. A peptide corresponding to the region of the PED S
protein containing the motif similar with the candidate phage
peptides was synthesized and also analyzed for inhibition
properties against the monoclonal antibody.
Table 1
Predominant peptides displayed by selected phages on their g3p minor coat
protein
Recovered phages a Displayed random peptide b
PED-PhD 4-01 S H R L P Y P
PED-PhD 4-02 S H R L P Y P
PED-PhD 4-03 S H R L P Y P
PED-PhD 4-10 S H R L P Y P
PED-PhD 4-11 S H R L P Y P
PED-PhD 4-12 S H R L P Y P
PED-PhD 4-06 S H R L P Q V
PED-PhD 4-04 G P R P V T H
PED-PhD 4-05 G P R P V T H
PED-PhD 4-07 G P R P V T H
These displayed peptides show high binding affinity to the anti-PEDV
monoclonal antibody 2C10 after multiple panning.
a Isolated recombinant phages after 4 sets of bio-panning.
b Seven-mer peptide displayed on the g3p minor coat protein of the
recombinant phage.
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Selection of PEDV-neutralizing monoclonal antibodies
In this study, four different monoclonal antibodies (2D11,
2E4, 3H8 and 2C10) were tested for neutralizing activities
against KPEDV-9. As shown in Fig. 1, 1:100 dilution of MAbs
2D11 and 2C10 were able to neutralize more than 50% of
KPEDV-9 (55% and 84%, respectively), while 2E4 and 3H8
had lower neutralizing activities (30% and 11% neutralization,
respectively). At higher dilutions, however, only 2C10
exhibited neutralizing activities (58% neutralization at 1:400
dilution, 27% at 1:1600 and 19% at 1:6400). The other MAbs
had an average neutralizing activity of 8% at 1:400 and less than
1% at 1:1600. Based on these results, 2C10 was selected for
bio-panning of the phage peptide library.
Screening of 2C10-binding phages
In bio-panning the 7-mer phage peptide library with 2C10, a
total of 8395 recombinant phages were initially recovered. On
second panning, Polysorbate 20 (Tween-20, Sigma) concen-
tration in the washing buffer was elevated from 0.1% to 0.5%
to increase selection by removing phages having only weak to
moderate binding affinities. This resulted in the recovery of
only 960 strong binding recombinant phages. In subsequent
panning, the number of strong binding phages recovered
increased dramatically. Third panning resulted in the recovery
of approximately 290,950 recombinant phages while fourth
panning recovered approximately 393,300 recombinant
phages. The significant increase in the number of recovered
phages after third and fourth panning indicated that these
phages have a relative strong binding affinity to the 2C10
monoclonal antibody.Fig. 1. Plaque reduction neutralization test. Monoclonal antibodies (2C10, 2D11, 2E
activity. KPEDV-9 (1 × 103 pfu/ml) mixed with pre-immune mouse sera (1/100) serSequence analyses of recovered phages
After fourth panning, recombinant phages that exhibited
relative strong binding affinity to 2C10 were eluted, amplified,
and sequenced. In Table 1, the sequence of the heptapeptide-
gIII-fusion region of 10 randomly selected phages revealed the
predominance of 2 peptide motifs: SHRLP(Y/Q)(P/V) accounts
for 70% (7 out of 10) of the selected phages while GPRPVTH
accounts for 30% (3 out of 10). In the SHRLP(Y/Q)(P/V) motif,
the 6th position is occupied either by tyrosine or glutamine,
amino acids that share similar biochemical properties (neutral-
polar and hydrophilic). The 7th position is occupied either by
proline or valine. These two amino acids also share similar
biochemical properties (neutral-nonpolar and hydrophobic).
The relatively strong binding affinity of these two peptides4, 3H8) at various dilutions were mixed with PEDV to determine neutralizing
ved as negative control.
Fig. 2. Sequence alignment of PEDV spike protein. The peptide motif SHRLPYP (represented by PED-PhD 4-01) and GPRPVTH (represented by PED-PhD 4-04)
were aligned with PEDV CV777 (NCBI accession number AAK38656) using Lipman–Pearson approach. The transmembrane domain was identified by SOSUI
(http://sosui.proteome.bio.tuat.ac.jp).
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neutralizing epitope on PEDV, either in terms of sequence
similarity, structural similarity, or both.
Mapping the peptide motifs on known PEDV sequence
The probable location of SHRLPYP and GPRPVTH on
PEDV was determined by pair-wise alignment using the
Lipman–Pearson approach. A Ktuple value of 2 and a gap
penalty length of 12 revealed a single location on the PEDV S
protein where both peptide sequences gave the highest match
(Fig. 2). SHRLPYP showed a similarity index of 50% to the
native sequence GPRLQPY (aa 1368–1374), while the first 3
amino acids of GPRPVTH were identical with the native
sequence. Analysis on the membrane topology of the PED SFig. 3. Neutralization inhibition assay. PRNTof KPEDV-9 by 2C10 in the presence of
activity of 2C10 against KPEDV-9 (VC = KPEDV-9; VC + 2C10 = KPEDV-9 + MA
Ph-SHRLPYP = VC + MAb 2C10 + phage-SHLRPYP; Ph-GPRPVTH = VC + MAprotein revealed the location of 1368GPRLQPY1374 at the C-
terminal region of the glycoprotein.
Characterization of selected phages
To determine whether the recovered phages displaying
SHRLPYP or GPRPVTH on their g3p minor coat protein have
similar properties with a neutralizing epitope on PEDV, these
phages were tested for inhibition of MAb 2C19′s neutralizing
activity. Fig. 3 compares the neutralizing activity of 2C10 on
KPEDV-9 in the presence of varying amounts of phages. In the
absence of recombinant M13 phages, 2C10 neutralized more
than 90% of pre-titered KPEDV-9 (data not shown). However,
phages displaying the SHRLPYPmotif completely inhibited the
neutralizing activity of 2C10 at a dilution of 1:100. Higher2C10 binding phages. Percent inhibition represents the reduction of neutralizing
b2C10; VC + 2C10 + Ph-C = KPEDV-9 + MAb2C10 + nonselected M13 phage;
b2C10 + phage-GPRPVTH).
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inhibiting properties against 2C10 (47.2% and 30.2%, respec-
tively). A similar trend was observed for phages displaying
GPRPVTH. Phage dilution of 1:100 completely inhibited
neutralizing activity of 2C10 while higher dilutions of this
phage (1:500 and 1:2500) resulted in lower inhibitions (66.1%
and 20.8%, respectively). In contrast, when nonspecific M13
phage was pre-incubated with 2C10, only 13.2% of the
neutralizing activity of the antibody was inhibited. These data
suggest that phages specifically displaying the SHRLPYP and
GPRPVTH peptides are able to block the neutralizing activity
of 2C10 against KPEDV-9.
Characterization of the 1368GPRLQPY1374 motif
Based on the results of protein sequence alignment, two peptides
were synthesized. Peptide S-CT(24) (ACFSGCCRGPRLQ-
PYEAFQK VHVQ) corresponded with the C-terminal cyto-
plasmic domain of the S protein, including the GPRLQPYmotif
which showed high similarity index with the phage displayed
peptides. Peptide S-CT(17) (ACFSGCCREAFQKVHVQ) is
similar to the S-CT(24) but does not include the GPRLQPY
motif. In the neutralization inhibition assay, 10 μg/ml S-CT(24)
blocked 67.9% of 2C19's neutralizing activity. In contrast,
S-CT(17) was observed to block the neutralizing activity of
2C10 by only 9.5% with the same concentration. (Fig. 4).
Discussion
Current research on alternative vaccine strategies for PEDV
has focused mainly on the CO-26K equivalent (COE). The CO-
26K (collagenase digested fragment) is a conserved region
discovered on the S protein of TGEVand was previously shown
to include most of the critical epitopes important for virusFig. 4. Neutralization inhibition assay using synthetic peptides. Synthetic peptides S-
protein) and S-CT(17) (modified version of S-CT(24) with the GPRLQPY motif
VC + 2C10 = KPEDV9 + MAb2C10; S-CT(24) = KPEDV-9 + MAb2C10 + S-CT(neutralization (Delmas et al., 1986, 1990). Chang et al. (2002)
expressed the recombinant COE in E. coli and used that to
generate polyclonal antibodies in mice. The antibodies were
demonstrated to possess neutralizing activity against PEDV in
plaque assay experiments using Vero cells as host. However,
sequence comparison among PEDV strains identified in recent
outbreaks in Korea (Cruz et al. unpublished data) revealed
numerous differences on the COE domain of the S protein,
implying that antibodies that recognize critical epitopes on the
COE of one strain of PEDV may not be able to recognize that of
another strain.
In this study, we identified the peptide sequence recognized
by 2C10, a monoclonal antibody that has neutralizing activity
against PEDV, using a phage peptide library. Our findings
revealed two peptide motifs, SHRLP(Y/Q)(P/V) and
GPRPVTH. Phages displaying these peptides showed strong
binding affinity to 2C10 and demonstrated their ability to block
the neutralizing activity of 2C10. It is quite interesting to note
that these peptides were found to share a homology with the
region on the C-terminal cytoplasmic tail of the S protein. Two
peptide molecules were synthesized based on this region. The S-
CT(24) which contained the GPRLQPY motif inhibited the
PEDV neutralizing activity of 2C10. In contrast, S-CT(17)
which had the GPRQPY motif deleted, failed to inhibit the
neutralizing activity of 2C10. This strengthens our hypothesis
that the phage peptides SHRLP(Y/Q)(P/V) and GPRPVTH
share antigenic similarities with the 1368GPRLQPY1374 motif
found on the cytoplasmic domain of the S protein. Because of
the inaccessibility of this region in intact virions to neutralizing
antibodies, it raises the question of whether the C-terminal
endodomain of the S protein indeed has a neutralizing epitope
or that the newly identified peptide sequence share a structural
similarity with a conformational epitope in another region of the
glycoprotein.CT(24) (corresponding to the 24 aa C-terminal cytoplasmic domain of PEDV S
removed) were co-incubated with PEDV and MAb2C10 (VC = KPEDV-9;
24); S-CT(17) = KPEDV-9 + MAb2C10 + S-CT(17)).
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the virus replication cycle, namely the attachment and entry
into the host cell. This is usually mediated by antibodies that
block the receptor binding sites on the surface of the virus or
other related sites involved in virus integration into the host.
Most of the neutralizing epitopes involved with virus
attachment and entry are located on the surface of the virus
and are easily accessible to the antibodies. However, some
epitopes may exist on sites that are thought to be inaccessible
to antibodies (Cleveland et al., 2003). Until now, only a few
neutralizing epitopes located on the cytoplasmic domain of
transmembrane proteins have been identified. The envelope
glycoprotein gp41 in HIV-1 was first reported to contain the
neutralizing epitope 746ERDRD750 at the C-terminal endodo-
main (Broliden et al., 1992; Vella et al., 1993). However, this
finding has been highly controversial since antibodies cannot
cross the lipid bilayer envelope membrane. Buratti et al. (1997)
suggested that this discrepancy can be explained by the
existence of a similar epitope exposed on the ectodomain of the
p17 matrix protein which is cross-reacting with the antibodies
directed to the gp41 epitope. Incidentally, this transmembrane
protein is involved in virus replication and has been a target of
several candidate HIV-1 vaccines (Boucher et al., 1990; Naylor
et al., 1987). Cheung et al. (2005) proposed a theoretical model
that suggests that the C-terminal of gp41 spans the membrane
several times and that the 746ERDRD750 epitope is constantly
exposed on the surface of HIV-1. At present, the exact
topology of the 746ERDRD750 and how antibodies that bind
specifically to this epitope are able to inhibit virus infection is
not fully known.
Peptide residues of a linear or continuous epitope are
located side by side on the secondary and tertiary structures
of protein molecules. In contrast, peptide residues of a
conformational or discontinuous epitope maybe several
amino acids apart on a linearized protein but are spatially
juxtaposed in a folded protein resulting from internal
disulfide bonds, addition of carbohydrate side-chains and
other post-translational modifications. Coronaviruses have
highly complex peplomers. The S protein is about 175 to
180 kDa and forms a homotrimer with a highly glycosylated
terminal. It also contains two hydrophobic (heptad) repeat
regions that forms the fusion core complex (Delmas et al.,
1986; Jan Bosch et al., 2003). In the case of PEDV, the S
protein is a 1383- to 1386-amino-acid transmembrane
glycoprotein that has 27 to 29 potential N-linked glycosyl-
ation sites, a stretch of hydrophobic residues proximal to the
C-terminal believed to function as the membrane anchor, and
lacks the proteolytic cleavage site to yield cleaved amino and
carboxy subunits S1 and S2, similar to the TGEV subset
(Duarte and Laude, 1994; Yeo et al., 2003). There is the
likelihood that the 2C10 monoclonal antibody recognizes a
discontinuous epitope on PEDV that is structurally similar
with the SHRLP(Y/Q)(P/V) and GPRPVTH peptides.
Combinatorial peptide libraries, like the phage peptide
library, are useful tools in identifying the primary sequence of
a target epitope by probing with monoclonal antibodies that
recognize continuous epitopes (Liu et al., 2003; Scott andSmith, 1990). However, when a monoclonal antibody used to
probe the peptide library recognize a discontinuous epitope, the
resulting peptide sequences may vary or may not match any
regions on the target protein (D'Mello et al., 1999; Geysen et
al., 1984). Although such characteristic limits the ability of this
technique in identifying the primary sequence of discontinuous
epitopes, the use of peptide libraries does offer the advantage of
determining antigen–antibody interaction and structural ho-
mology between discontinuous epitopes and linear peptides
(Al-Bukhari et al., 2002; Houghten, 1985). For the past decade,
phage peptide libraries have been used extensively to identify
the primary sequences of continuous and discontinuous
epitopes of different viruses like dengue virus (Wu et al.,
2003), human papillomavirus (Santamaria et al., 2001),
hepatitis C virus (Petit et al., 2003), porcine reproductive, and
respiratory virus (Ostrowski et al., 2002), HIV (Scala et al.,
1999) and coronaviruses like MHV (Yu et al., 2000) and SARS
CoV (Zhong et al., 2005). Aside from identifying probable
epitopes, these functional linear epitopes can be used as
mimitopes in subunit vaccines. Several candidate subunit
vaccines derived from phage peptide libraries have been tested
against certain diseases (Meola et al., 1995; Puntoriero et al.,
1998; Tumanova et al., 2001).
Our discovery of two linear peptides cross reacting with a
PEDV neutralizing monoclonal antibody offer a new perspec-
tive on the membrane topology of the S protein as well as
provide valuable information regarding the characteristic of a
neutralizing epitope. Because of the high degree of conforma-
tion on the S protein, using linear epitopes that elicit production
of cross reacting antibodies capable of neutralizing PEDVoffers
a simple but effective alternative strategy in developing
recombinant vaccines for PED.
Materials and methods
Cell and virus
Cell-adapted PEDV (KPEDV-9) was kindly provided by the
National Veterinary Research and Quarantine Services of
Korea. The virus was cultured in Vero cells supplemented by
Eagle's minimal essential medium (EMEM, Invitrogen) con-
taining 0.001% trypsin (Invitrogen) according to the method
described by Hofmann and Wyler (1988). Briefly, stock virus
was inoculated to a confluent monolayer of Vero cells and
placed at 37 °C, 5% CO2. After 24 h, progeny virions were
harvested, and titer was determined by plaque assay as
described by Vautherot (1981). Ten-fold serially diluted
KPEDV-9 was inoculated in 35-mm diameter TC dishes (SPL
Labware) containing confluent monolayer of Vero cells at
37 °C. After 1 h, the monolayer was overlaid with 1% agarose in
EMEM supplemented with 0.001% trypsin and incubated at
37 °C, 5% CO2. A second overlay containing 0.01% neutral red
was added for staining after 24 h. When visible plaques
appeared, the monolayer was fixed with 3.5% formaldehyde in
phosphate-buffered saline (PBS, pH 7.2) then permanently
stained with crystal violet solution (0.01% crystal violet, 2.5%
ethanol in PBS) for plaque counting and titration.
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Monoclonal antibodies 2D11, 2E4 and 3H8 were generously
provided by Bioleaders Corp., Inc., Korea, while 2C10 was
kindly provided by Dr. Kweon of the National Veterinary
Research and Quarantine Service. The neutralizing activities of
the four MAbs were determined by plaque reduction neutral-
ization test (PRNT) following the method mentioned previously
(Beaty et al., 1989). Four-fold serially diluted MAbs were
mixed with pre-titered KPEDV-9 (100 pfu) at 37 °C for 30 min
and inoculated to 35-mm diameter TC dishes containing Vero
cell monolayer. After 1-h incubation at 37 °C for 1 h, the
monolayer was overlaid with 2.5 ml 1% agarose in EMEM
supplemented with 0.001% trypsin and continued incubation at
37 °C, 5% CO2. After 24 h, second agarose overlay containing
0.01% neutral red was added. The cell monolayers were fixed
with 3.5% formaldehyde in PBS after 24 h, then permanently
stained with crystal violet solution. The monoclonal antibody
that reduced plaque formation by more than 50% at a dilution of
1:400 was used for screening of the phage peptide library.
Screening of phage displayed peptide library
Seven-mer phage displayed peptide libraries (New England
Biolabs) was bio-panned with the selected MAb and titrated by
plaque assay according to manufacturer's instructions. Briefly, a
well of a 96-well microtiter plate was sensitized with 25 μg of
selected MAb and incubated at 4 °C overnight. Blocking was
performed with 350 μl of BSA (5 mg/ml) in 50 mM Tris-
buffered saline (TBS) for 1 h at room temperature followed by
six times washing with 50 mM TBS containing 0.1% Tween 20
(0.1% TBS-T) to remove excess antibody and blocking reagent.
Approximately 2 × 1011 pfu recombinant phages were added to
the well and incubated for 1 h. Unbound phages were removed
by ten times washing with 0.1% TBS-T. Antibody-bound
phages were eluted by treatment with 100 μl of 0.2 M Glycine-
HCl (pH 2.2) followed by 15 μl of 1M Tris–Cl (pH 9.1)
containing BSA. The eluted phages were amplified in log phase
E. coli ER2738 and harvested in the culture supernatant at
12,000 × g for 10 min and concentrated by PEG/NaCl
precipitation. Bio-panning was repeated 3 times on amplified
phage eluate using a wash buffer containing 0.5% Tween 20
(0.5% TBS-T) to enrich the pool of phages with strong binding
affinity to the MAb. Eluted and amplified phages were titrated
after each panning.
Sequencing of MAb specific recombinant phages
Following manufacturer's instructions, 10 phage colonies
recovered after fourth panning were randomly selected and
amplified. Each selected phage colony was excised from the
bacterized agar and cultured in E. coli ER2738. Phage genomic
DNAwas extracted by treatment with Iodide buffer (pH 8.0) and
purified by ethanol precipitation. The phage heptapeptide-gIII
fusion gene was sequenced, and the corresponding amino acid
sequence of the heptapeptide was deduced from the resulting
nucleotide sequence using the reduced genetic code chart.Mapping the putative PEDV neutralizing epitope
The amino acid sequences derived from the phage displayed
peptides were compared with known PEDV sequence from
NCBI. Sequence similarity between the phage displayed
peptides and native PEDV proteins was determined using
DNAStar Megalign™ 5.0. A topology prediction program
(http://sosui.proteome.bio.tuat.ac.jp) was used to predict the
location of the identified motif on the virus surface.
Neutralization inhibition assay
Synthetic peptides corresponding to the regions showing
neutralizing activities against PEDV were designed and
purchased from Any Gen (Korea). Both recombinant phages
demonstrating relatively strong binding to the PEDV MAb and
the synthetic peptides were tested for inhibition of the MAb's
neutralizing activity. The selected MAb was pre-treated with
four-fold serially diluted recombinant phages or various
concentrations of the synthetic peptides at 37 °C for 10 min
then mixed with pre-titrated KPEDV-9 (50 pfu) for 30 min. The
mixture was added to 35-mm diameter TC dishes containing
Vero cell monolayer and incubated at 37 °C for 1 h similar to
plaque assay method described previously. Percent inhibition of
recombinant phages or synthetic peptides to the neutralizing
activity of the PEDV MAb was compared.
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